• SU 5402: Advanced Tyrosine Kinase Inhibition for Translation

  2026-05-25

  Explore how SU 5402, a potent tyrosine kinase inhibitor, transforms translational research in cell signaling and cancer biology. This article provides an in-depth look at SU 5402’s mechanism, unique assay insights, and cross-domain applications.

• Dextromethorphan Hydrobromide: Strategic Insights for Neurop

  2026-05-25

  Explore the mechanistic underpinnings and translational potential of dextromethorphan hydrobromide as a high-purity NMDA receptor antagonist in neuroprotection research. This article provides advanced guidance for researchers, contextualizes evidence from allied metabolic disease studies, and illustrates best practices for preclinical workflows.

• Synergistic CDK4/6 and BET Inhibition Suppresses PDAC Progre

  2026-05-24

  Gu et al. (2025) demonstrate that combined CDK4/6 and BET inhibition achieves synergistic suppression of tumor growth and epithelial-to-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma (PDAC) by modulating the GSK3β-mediated Wnt/β-catenin pathway. This approach not only inhibits proliferation but also reverses pro-metastatic effects often seen with CDK4/6 inhibitors alone, informing rational combination strategies for targeting aggressive PDAC.

• Leucovorin Calcium: Optimizing Methotrexate Rescue in Tumor

  2026-05-23

  Leucovorin Calcium (calcium folinate) empowers advanced cancer researchers to precisely model antifolate drug responses and protect cells from methotrexate-induced suppression in complex assembloid systems. This guide translates the latest high-complexity gastric cancer model findings into robust experimental workflows and troubleshooting strategies, leveraging APExBIO’s high-purity reagent.

• SU5416 (Semaxanib): Redefining Vascular and Tumor Research

  2026-05-22

  Explore how SU5416 (Semaxanib) advances angiogenesis inhibition and immune modulation. This thought-leadership article integrates mechanistic insights, translational relevance, and strategic guidance for researchers targeting tumor vascularization, pulmonary vascular remodeling, and beyond. Drawing on the latest findings in vascular cell signaling and referencing essential workflow resources, we chart new directions for SU5416’s application in preclinical and translational research.

• Cholesterol Impairs Intracellular Trafficking of Lipid Nanop

  2026-05-22

  This study uncovers how elevated cholesterol levels in lipid nanoparticles (LNPs) hinder their intracellular trafficking and nucleic acid delivery efficiency by promoting trapping in peripheral early endosomes. These findings refine our understanding of LNP formulation design for improved delivery of genetic cargo.

• Nelfinavir Mesylate: HIV-1 Protease Inhibitor in Advanced As

  2026-05-21

  Nelfinavir Mesylate empowers both HIV replication suppression and ferroptosis modulation, uniquely bridging antiviral and cell death research. Explore optimized workflows, troubleshooting strategies, and the latest insights on DDI2-NFE2L1 targeting to maximize reproducibility and translational value.

• Protein A/G Magnetic Beads: Precision Tools for Protein Inte

  2026-05-21

  Protein A/G Magnetic Beads from APExBIO set a new benchmark for immunoprecipitation and protein-protein interaction assays, providing high specificity and minimal background in complex samples. This article delivers actionable protocols, troubleshooting guidance, and translational insights, drawing on cutting-edge cancer stem cell research to help researchers maximize assay fidelity and discover actionable biology.

• Aminocoumarin HO-1 Probe Reveals Non-Transcriptional Regulat

  2026-05-20

  This paper introduces AMC-Hem, a red-shifted aminocoumarin-based fluorescent probe, enabling real-time imaging of heme oxygenase-1 (HO-1) activity in live human macrophages. The study uncovers previously unrecognized non-transcriptional regulation mechanisms for HO-1, with implications for cardiovascular and inflammatory disease research.

• Stattic STAT3 Inhibitor: Applied Workflows in Cancer Researc

  2026-05-20

  Stattic empowers researchers to dissect STAT3-driven cancer mechanisms, optimize apoptosis induction, and enhance radiosensitivity, especially in head and neck squamous cell carcinoma models. Discover protocol-ready workflows, troubleshooting strategies, and translational insights that set Stattic apart as a precision STAT3 inhibitor.

• HyperScribe T7 High Yield Cy5 RNA Labeling Kit: Optimized Pr

  2026-05-19

  The HyperScribe T7 High Yield Cy5 RNA Labeling Kit empowers researchers to generate high-sensitivity fluorescent RNA probes with customizable labeling density, streamlining complex workflows for in situ hybridization and viral RNA studies. Robust performance, tunable Cy5-UTP incorporation, and compatibility with challenging templates set this Cy5 RNA labeling kit apart for advanced molecular applications.

• Spleen-Targeted mRNA Vaccines Induce TLS in Hepatocellular C

  2026-05-19

  Lin et al. present a spleen-targeted neoantigen mRNA vaccine (STNvac) that robustly activates ISG15+ CD8+ T cells and promotes tertiary lymphoid structure (TLS) formation in hepatocellular carcinoma. This study uncovers mechanistic details behind organ-targeted mRNA immunotherapies and highlights opportunities for translational cancer vaccine development.

• Mitochondrial Apoptosis and Muscle Atrophy in Ovarian Cancer

  2026-05-18

  This study elucidates how mitochondrial ROS-driven apoptosis, but not necroptosis, is regulated in skeletal muscle during ovarian cancer cachexia. Despite suppressing apoptotic caspase activity with SkQ1, muscle atrophy persisted, indicating apoptosis and necroptosis are not direct drivers of atrophy in this context.

• Applied Cefazedone (Refosporen): Protocols for Antibacterial

  2026-05-18

  Cefazedone (Refosporen) unlocks reliable, β-lactamase-resistant workflows for in vitro and in vivo antibacterial applications targeting both Gram-positive and Gram-negative pathogens. This article translates experimental insights and reference findings into actionable protocols and troubleshooting strategies, empowering researchers to optimize their antibacterial testing pipelines with APExBIO’s trusted reagent.

• Amyloid Beta-peptide (25-35): Shaping Translational AD Resea

  2026-05-17

  This article provides translational researchers with a mechanistically anchored, evidence-driven guide to deploying Amyloid Beta-peptide (25-35) (Aβ25-35) as a neurotoxicity and microglial polarization model in Alzheimer's disease (AD) research. Integrating recent discoveries around the FLOT1–FOSL2–EphA2 axis and best practices in neurodegenerative workflows, we chart a strategy for high-impact, reproducible studies, and highlight the unique positioning of APExBIO’s Aβ25-35 in the competitive landscape.

15990 records 1/1066 page Next 12345 下5页 Last page